DocMorris stock closed at CHF10.00 on the day of its latest earnings, capping a volatile few months that included a sharp rebound over the past quarter. The market has been treating DocMorris as a high growth, online pharmacy bet. The headline from the latest numbers is more sobering. Revenue over the last twelve months reached about CHF1.1b, yet the company still reported a sizeable loss from continuing operations and a loss per share in the mid single digit CHF range.
The expectation gap is clear for you as a shareholder. The growth story remains tied to sales momentum, while the real pressure point this time is the ongoing drag from unprofitable operations.
Is DocMorris trading at a bargain P/S multiple, or does it simply reflect the risk of ongoing losses? See how the stock’s sales-based valuation compares with peers in our valuation analysis for DocMorris
H1 2026 Earnings Summary
- Revenue (TTM to H1 2026 vs. TTM to H1 2025): CHF1,124.5m vs. CHF1,017.0m (higher revenue base on a trailing twelve month view)
- Net Loss from Continuing Operations (TTM to H1 2026 vs. TTM to H1 2025): loss of CHF134.4m vs. loss of CHF97.3m (larger loss on a trailing twelve month view)
- Basic EPS (TTM to H1 2026 vs. TTM to H1 2025): loss of CHF3.47 per share vs. loss of CHF8.25 per share (smaller loss per share on a trailing twelve month view)
Prefer clean, visual charts over scrolling through dense financial tables and earnings PDFs? See an at a glance view of DocMorris, including its financial health and profitability trends, in the interactive company report for DocMorris.
DocMorris Bullish Hopes Meet Mixed Earnings Signals
For a bullish view on DocMorris, the key support is that revenue on a trailing twelve month basis now sits at about CHF1.1b. That points to a business that continues to attract demand for its online pharmacy and digital health services. The smaller loss per share over the same period also hints that dilution from losses is easing. For investors who back the long term shift to digital healthcare, this combination of a higher sales base and lower per share loss can still fit a cautiously optimistic story.
Losses Keep The DocMorris Bear Case Alive
The bearish side of the DocMorris story still finds plenty of fuel. The loss from continuing operations has widened to CHF134.4m on a trailing twelve month view, even with the higher revenue base. That points to ongoing pressure from costs in an already competitive and regulated market. The share price is up over 50% in the past 90 days, so expectations have moved ahead of the earnings trend. Until losses begin to contract in absolute terms, concerns about the resilience of the business model remain very much in play.
Access the analyst roadmaps that sit behind DocMorris at CHF10.0 and see where the consensus breaks across revenue, margin and cash flow in the next few years with the full analyst estimates for DocMorris.
Stay Ahead With Simply Wall St
If the recent volatility in DocMorris, paired with ongoing losses, has your attention, register for free with Simply Wall St and add it to a Watchlist so you can track the share price against fair value and watch for a more attractive entry point. After you own the stock, use the Portfolio Command Center to cut through daily noise and focus on the key updates that matter for your holdings. For longer term context, tap into crowd insights and debate through the Community to see how other investors are interpreting the same numbers. This way you can spot hidden catalysts or early warning signs sooner and stay ahead of the market.
Seeking Alternatives Beyond DocMorris?
Fresh stock ideas can move from quiet to flying once early buyers spot momentum. Check these under the radar for now before the crowd catches up, and consider them promptly.
- Spot resilient compounders with strong balance sheets before they attract wider attention by scanning the curated list of solid balance sheet and fundamentals stocks (434 results).
- Review carefully filtered 449 dividend fortresses to explore potential income trends while yields and prices still look compelling for long term holders.
- Screen focused 55 AI infrastructure stocks to track fast-moving infrastructure themes supporting AI growth while the data is fresh and under-followed.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com